Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
New medicines: EU opinions and licences, US approvals
CHMP opinions and European Commission licences from the European Medicines Agency, and new medicines approved by the US FDA. Shown in the regulator's own words, with a link to the source; checked every two hours. This is regulatory news, not medical advice, and not sponsored.
November 2026
EU · CHMP positive opinion
Aumolertinib (Aumseqa)
Treatment of non-small cell lung cancer in adults.
CHMP opinion 12 Nov 2026 · SFL Pharmaceuticals Deutschland GmbH
EU · CHMP positive opinion
Baxdrostat (Baxfendy)
Treatment of hypertension in adults.
CHMP opinion 12 Nov 2026 · AstraZeneca AB
EU · CHMP positive opinion: new indication
Belzutifan (Welireg)
New indication (Carcinoma, Renal Cell, von Hippel-Lindau Disease). The wording is on the EMA page.
Conditional
CHMP opinion 12 Nov 2026 · Merck Sharp & Dohme B.V.
EU · CHMP positive opinion: new indication
Clesrovimab (Enflonsia)
New indication (Respiratory Syncytial Virus Vaccines). The wording is on the EMA page.
CHMP opinion 12 Nov 2026 · Merck Sharp Dohme Limited
EU · CHMP positive opinion: new indication
Dolutegravir (Tivicay)
New indication (HIV Infections). The wording is on the EMA page.
CHMP opinion 12 Nov 2026 · ViiV Healthcare BV
EU · CHMP positive opinion: new indication
Dolutegravir;lamivudine (Dovato)
New indication (HIV Infections). The wording is on the EMA page.
CHMP opinion 12 Nov 2026 · ViiV Healthcare B.V.
EU · CHMP positive opinion: new indication
Ertugliflozin (Steglatro)
New indication (Diabetes Mellitus, Type 2). The wording is on the EMA page.
CHMP opinion 12 Nov 2026 · Merck Sharp & Dohme B.V.
EU · EU licence (European Commission)
Glepaglutide (Zeydovio)
Zeydovio is indicated for the treatment of adults with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.
CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Zealand Pharma A/S
EU · CHMP positive opinion: new indication
Lenacapavir (Sunlenca)
New indication (HIV Infections). The wording is on the EMA page.
CHMP opinion 12 Nov 2026 · Gilead Sciences Ireland Unlimited Company
EU · CHMP positive opinion: new indication
Meningococcal group B Vaccine (rDNA, component, adsorbed) (Bexsero)
New indication (Meningitis, Meningococcal). The wording is on the EMA page.
CHMP opinion 12 Nov 2026 · GSK Vaccines S.r.l.
EU · CHMP positive opinion: new indication
Obinutuzumab (Gazyvaro)
Gazyvaro is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE) despite standard therapy.
CHMP opinion 12 Nov 2026 · Roche Registration GmbH
EU · CHMP positive opinion: new indication
Osilodrostat (Isturisa)
New indication (Cushing Syndrome). The wording is on the EMA page.
Orphan
CHMP opinion 12 Nov 2026 · Recordati Rare Diseases
EU · EU licence (European Commission)
Povorcitinib (Povofortay)
Povofortay is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to, or who are intolerant or contraindicated to an anti-TNF therapy.
CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Incyte Biosciences Distribution B.V.
EU · CHMP positive opinion: new indication
Secukinumab (Cosentyx)
Adolescent hidradenitis suppurativa (HS) Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents 12 years and older with an inadequate response to conventional systemic HS therapy (see section 5.1).
CHMP opinion 12 Nov 2026 · Novartis Europharm Limited
EU · CHMP positive opinion
Sintilimab (Zybrivo)
Treatment of non-squamous non-small cell lung cancer in adults.
CHMP opinion 12 Nov 2026 · Fortvita Biologics (Ireland) Limited
EU · CHMP positive opinion: new indication
Talazoparib (Talzenna)
New indication (Breast Neoplasms). The wording is on the EMA page.
CHMP opinion 12 Nov 2026 · Pfizer Europe MA EEIG
October 2026
EU · EU licence (European Commission)
Linerixibat (Lynavoy)
Lynavoy is indicated for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
Orphan
CHMP opinion 23 Jul 2026 → EU licence 22 Oct 2026 · GlaxoSmithKline Trading Services Limited
EU · CHMP positive opinion
Daraxonrasib (Rasonque)
Treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
Orphan
CHMP opinion 15 Oct 2026 · Revolution Medicines Netherlands B.V.
EU · CHMP negative opinion
Narsoplimab (Yartemlea)
Treatment of patients with haemopoietic stem cell transplant-associated thrombotic microangiopathy
Negative
CHMP opinion 15 Oct 2026 · Omeros Ireland Limited
EU · CHMP positive opinion
Navepegritide (Yuviwel)
Treatment of achondroplasia in children
Orphan
CHMP opinion 15 Oct 2026 · Ascendis Pharma Growth Disorders A/S
EU · CHMP positive opinion
Orforglipron (Foundayo)
Treatment of obesity and type 2 diabetes mellitus in adults
CHMP opinion 15 Oct 2026 · Eli Lilly Nederland B.V.
EU · CHMP positive opinion: new indication
Insulin icodec;semaglutide (Kyinsu)
New indication (Diabetes Mellitus, Type 2). The wording is on the EMA page.
CHMP opinion 15 Oct 2026 · Novo Nordisk A/S
EU · CHMP positive opinion: new indication
Pandemic influenza vaccine (H5N1) (live attenuated, nasal) (Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune))
New indication (Influenza, Human). The wording is on the EMA page.
Conditional
CHMP opinion 15 Oct 2026 · AstraZeneca AB
EU · CHMP positive opinion: new indication
Talquetamab (Talvey)
Talvey is indicated: in combination with daratumumab and pomalidomide or in combination with daratumumab, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who… Show the full indication
Talvey is indicated: in combination with daratumumab and pomalidomide or in combination with daratumumab, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy. Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. Note: New text in bold CHMP post-authorisation summary of positive opinion for Talvey (VR-0000339914) Adopted Reference Number: EMADOC-1700519818-3395421 English (EN) (123.5 KB - PDF) First published: 16/10/2026 View Key facts Name of medicine Talvey EMA product number EMEA/H/C/005864 Active substance talquetamab International non-proprietary name (INN) or common name talquetamab Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutical chemical (ATC) code L01FX29 Additional monitoring This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicin
ConditionalPRIME
CHMP opinion 15 Oct 2026 · Janssen-Cilag International N.V.
EU · CHMP positive opinion
Temozolomide (Kizfizo)
Treatment of adults with glioblastoma multiforme and children with malignant glioma
Orphan
CHMP opinion 15 Oct 2026 · ORPHELIA Pharma
EU · CHMP positive opinion: new indication
Tucatinib (Tukysa)
HER2-positive breast cancer Tukysa is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable or metastatic HER2-positive breast cancer following first-line chemotherapy.
CHMP opinion 15 Oct 2026 · Pfizer Europe MA EEIG
September 2026
EU · EU licence (European Commission)
Leriglitazone (Nezglyal)
Nezglyal is indicated for the treatment of Cerebral Adrenoleukodystrophy (cALD) in males with Adrenoleukodystrophy (ALD) aged 2 to 12 years with non Gadolinium (Gd) enhancing lesions (i.e. Gd negative) in brain Magnetic Resonance Imaging (MRI), with a Neurological Functional Score (NFS) of 0 or 1.
OrphanExceptional circumstances
CHMP opinion 23 Jul 2026 → EU licence 21 Sept 2026 · Minoryx Therapeutics S.L.
EU · EU licence (European Commission)
Ensitrelvir (Zokovea)
Post exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older
Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):
2 trials are being summarised and will appear here shortly.
CHMP opinion 23 Jun 2026 → EU licence 18 Sept 2026 · Shionogi B.V.
EU · EU licence (European Commission)
Icotrokinra hydrochloride (Icotyde)
Icotyde is indicated for the treatment of moderate to severe plaque psoriasis in adults, and adolescents 12 years of age and older and weighing at least 40 kg, who are candidates for systemic therapy
Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):
2 trials are being summarised and will appear here shortly.
CHMP opinion 23 Jul 2026 → EU licence 18 Sept 2026 · Janssen-Cilag International
EU · EU licence (European Commission)
Ranibizumab (Susvimo)
Susvimo is indicated in adult patients for the treatment of neovascular (wet) age-related macular degeneration (nAMD) who have achieved stable disease after previously responding to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicinal product.
Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):
2 trials are being summarised and will appear here shortly.
CHMP opinion 23 Jul 2026 → EU licence 18 Sept 2026 · Roche Registration GmbH
EU · CHMP negative opinion
Allogeneic faecal microbiota, pooled (Xervyteg)
Treatment of adult patients with acute-graft-versus-host disease (aGvHD)
Negative
CHMP opinion 17 Sept 2026 · MaaT PHARMA
EU · CHMP positive opinion: new indication
Dabigatran etexilate (Pradaxa)
New indication (Arthroplasty, Replacement, Venous Thromboembolism). The wording is on the EMA page.
CHMP opinion 17 Sept 2026 · Boehringer Ingelheim International GmbH
EU · CHMP positive opinion
Denecimig (Frehemgo)
Prophylaxis of bleeding episodes in patients with haemophilia A
CHMP opinion 17 Sept 2026 · Novo Nordisk A/S
EU · CHMP positive opinion
Ensartinib (Gevalka)
The treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
CHMP opinion 17 Sept 2026 · SFL Pharmaceuticals Deutschland GmbH
EU · CHMP positive opinion
Gefurulimab (Klygefa)
Treatment of adult patients with generalised myasthemia gravis (gMG)
CHMP opinion 17 Sept 2026 · Alexion Europe
EU · CHMP positive opinion: new indication
Melphalan flufenamide (Pepaxti)
New indication (Multiple Myeloma). The wording is on the EMA page.
CHMP opinion 17 Sept 2026 · Oncopeptides AB (publ)
EU · CHMP positive opinion: new indication
Pembrolizumab (Keytruda)
New indication (Melanoma, Hodgkin Disease, Carcinoma, Renal Cell). The wording is on the EMA page.
CHMP opinion 17 Sept 2026 · Merck Sharp & Dohme B.V.
EU · CHMP positive opinion
Rabies vaccine (inactivated) for human (VaxRabeo)
Pre-exposure and post-exposure prophylaxis against rabies in all age groups
CHMP opinion 17 Sept 2026 · Sanofi Winthrop Industrie
EU · CHMP positive opinion
Relacorilant (Lifyorli)
Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):
2 trials are being summarised and will appear here shortly.
Orphan
CHMP opinion 17 Sept 2026 · Corcept Therapeutics Netherlands B.V.
EU · CHMP positive opinion
Senaparib (Sepalna)
Maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer
Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):
1 trial is being summarised and will appear here shortly.
CHMP opinion 17 Sept 2026
EU · CHMP positive opinion: new indication
Somapacitan (Sogroya)
New indication (Growth). The wording is on the EMA page.
CHMP opinion 17 Sept 2026 · Novo Nordisk A/S
EU · CHMP positive opinion: new indication
Trastuzumab deruxtecan (Enhertu)
Early breast cancer Enhertu as monotherapy is indicated for the adjuvant treatment of adult patients with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment (for biomarker-based patient selection, see section 4.2).
Conditional
CHMP opinion 17 Sept 2026 · Daiichi Sankyo Europe GmbH
August 2026
EU · EU licence (European Commission)
Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture) (Aujemflu)
Prophylaxis of influenza in adults 50 years of age and older. Aujemflu should be used in accordance with official recommendations.
CHMP opinion 25 Jun 2026 → EU licence 20 Aug 2026 · Seqirus Netherlands B.V.
EU · EU licence (European Commission)
Levodopa;carbidopa (Hopledo)
Hopledo is indicated for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilised with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens.
CHMP opinion 25 Jun 2026 → EU licence 20 Aug 2026 · Zambon SpA
EU · EU licence (European Commission)
Trofinetide (Daybu)
Daybu is indicated for the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older.
Orphan
CHMP opinion 25 Jun 2026 → EU licence 20 Aug 2026 · Acadia Pharmaceuticals B.V.
July 2026
EU · EU licence (European Commission)
Colchicine (Colchicine Agepha Pharma)
Colchicine AGEPHA Pharma is indicated for secondary prevention of atherothrombotic events in adult patients with coronary disease stable for at least 6 months.
CHMP opinion 21 May 2026 → EU licence 24 Jul 2026 · Agepha Pharma s.r.o.
EU · CHMP negative opinion
Arimoclomol (Meplyffa)
Treatment of Niemann-Pick disease type C (NPC) in patients aged 6 months and older in combination with miglustat.
NegativeOrphan
CHMP opinion 23 Jul 2026 · Zevra Denmark A/S
EU · CHMP negative opinion
Catequentinib (Qezzaqar)
Treatment of synovial sarcoma or leiomyosarcoma.
NegativeOrphan
CHMP opinion 23 Jul 2026 · CATS Consultants GmbH
EU · CHMP positive opinion: new indication
Formoterol fumarate dihydrate;glycopyrronium;budesonide (Riltrava Aerosphere)
New indication (Pulmonary Disease, Chronic Obstructive). The wording is on the EMA page.
CHMP opinion 23 Jul 2026 · AstraZeneca AB
EU · CHMP positive opinion
Lerodalcibep (Lyrokaul)
It is indicated in adults with primary hypercholesterolaemia (heterozygous familial (HeFH) and non-familial) or mixed dyslipidaemia as an adjunct to diet.
CHMP opinion 23 Jul 2026 · LIB Therapeutics B.V.
EU · CHMP positive opinion
Obicetrapib (Ubeslo)
Treatment of primary hypercholesterolaemia or mixed dyslipidaemia.
CHMP opinion 23 Jul 2026 · A. Menarini International Licensing S.A.
EU · CHMP positive opinion
Obicetrapib;ezetimibe (Evlarco)
Treatment of primary hypercholesterolaemia or mixed dyslipidaemia.
CHMP opinion 23 Jul 2026 · A. Menarini International Licensing S.A.
EU · CHMP positive opinion: new indication
Sacituzumab govitecan (Trodelvy)
New indication (Breast Neoplasms, Triple Negative Breast Neoplasms). The wording is on the EMA page.
CHMP opinion 23 Jul 2026 · Gilead Sciences Ireland UC
EU · CHMP negative opinion
Sufentanil;ketamine (KemSu)
Treatment of acute pain in children aged 1 to less than 18 years.
Negative
CHMP opinion 23 Jul 2026 · Proveca Pharma Limited
EU · EU licence (European Commission)
Camizestrant (Etcamah)
Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine… Show the full indication
Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).
CHMP opinion 21 May 2026 → EU licence 20 Jul 2026 · AstraZeneca AB
EU · EU licence (European Commission)
Alpelisib (Vijoice)
Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)
OrphanConditional
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · Novartis Europharm Limited
EU · EU licence (European Commission)
Liraglutide (Liraglutide STADA)
Treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · STADA Arzneimittel AG
EU · EU licence (European Commission)
Liraglutide (Ablymico)
Treatment of weight management.
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · STADA Arzneimittel AG
EU · EU licence (European Commission)
Nerandomilast (Jascayd)
Jascayd is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). Jascayd is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · Boehringer Ingelheim International GmbH
EU · EU licence (European Commission)
TrenibotulinumtoxinE (Boey)
Boey is indicated for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines), when these have an important psychological impact in adult patients.
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · AbbVie Limited
June 2026
EU · EU licence (European Commission)
Onasemnogene abeparvovec (Itvisma)
Itvisma is indicated for the treatment of 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene in patients 2 years of age and older.
CHMP opinion 23 Apr 2026 → EU licence 30 Jun 2026 · Novartis Europharm Limited
EU · CHMP negative opinion
Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded (Tacquell)
Tacquell is indicated for the treatment of adult patients with unresectable stage IIIC to IV melanoma following prior anti-Programmed Death-1 (PD-1)-based checkpoint inhibitor treatment given either as first line treatment for unresectable stage III or IV disease, or given as (neo)adjuvant therapy.
Negative
CHMP opinion 25 Jun 2026 · Netherlands Cancer Institute
EU · CHMP positive opinion
Insulin efsitora alfa (Onswik)
Treatment of type 2 diabetes mellitus
CHMP opinion 25 Jun 2026 · Eli Lilly Nederland B.V.
EU · CHMP positive opinion: new indication
Datopotamab deruxtecan (Datroway)
New indication (Breast Neoplasms). The wording is on the EMA page.
CHMP opinion 25 Jun 2026 · Daiichi Sankyo Europe GmbH
EU · CHMP positive opinion: new indication
Ustekinumab (Stelara)
New indication (Psoriasis, Arthritis, Psoriatic, Crohn Disease). The wording is on the EMA page.
CHMP opinion 25 Jun 2026 · Janssen-Cilag International NV
EU · EU licence (European Commission)
Plozasiran (Redemplo)
Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).
Orphan
CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Arrowhead Pharmaceuticals Ireland Limited
EU · EU licence (European Commission)
Tolebrutinib (Cenrifki)
Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.
CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Sanofi Winthrop Industrie
May 2026
EU · EU licence (European Commission)
Furosemide (Bopediat)
Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.
CHMP opinion 26 Mar 2026 → EU licence 29 May 2026 · Proveca Pharma Limited
EU · EU licence (European Commission)
Lurbinectedin (Zepzelca)
Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
Orphan
CHMP opinion 26 Mar 2026 → EU licence 29 May 2026 · Pharma Mar S.A.
EU · EU licence (European Commission)
Tarlatamab (Imdylltra)
Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
Orphan
CHMP opinion 26 Mar 2026 → EU licence 29 May 2026 · Amgen Europe B.V.
EU · EU licence (European Commission)
Nadofaragene firadenovec (Adstiladrin)
Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
ConditionalAdvanced therapy
CHMP opinion 26 Mar 2026 → EU licence 28 May 2026 · Ferring Pharmaceuticals A/S
EU · CHMP positive opinion: new indication
Benralizumab (Fasenra)
New indication (Asthma). The wording is on the EMA page.
CHMP opinion 21 May 2026 · AstraZeneca AB
EU · CHMP negative opinion
Copper (64Cu) oxodotreotide (Deqtynet)
Positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine neoplasms (NENs).
NegativeOrphan
CHMP opinion 21 May 2026 · CIS bio international
EU · CHMP positive opinion: new indication
Enfortumab vedotin (Padcev)
New indication (Carcinoma, Transitional Cell, Urologic Neoplasms). The wording is on the EMA page.
CHMP opinion 21 May 2026 · Astellas Pharma Europe B.V.
EU · EU licence (European Commission)
Leniolisib (Joenja)
Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.
OrphanExceptional circumstances
CHMP opinion 26 Mar 2026 → EU licence 21 May 2026 · Pharming Technologies B.V.
EU · CHMP positive opinion: new indication
Pegvaliase (Palynziq)
New indication (Phenylketonurias). The wording is on the EMA page.
Orphan
CHMP opinion 21 May 2026 · BioMarin International Limited
EU · CHMP positive opinion: new indication
Pembrolizumab (Keytruda)
New indication (Melanoma, Hodgkin Disease, Carcinoma, Renal Cell). The wording is on the EMA page.
CHMP opinion 21 May 2026 · Merck Sharp & Dohme B.V.
April 2026
EU · EU licence (European Commission)
Levodopa;carbidopa (Onerji)
Onerji is indicated for the treatment of motor fluctuations in patients with advanced Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medicinal products.
CHMP opinion 26 Feb 2026 → EU licence 27 Apr 2026 · Tanabe Pharma GmbH
EU · EU licence (European Commission)
Mavorixafor (Xolremdi)
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
OrphanExceptional circumstances
CHMP opinion 26 Feb 2026 → EU licence 27 Apr 2026 · Norgine B.V.
EU · CHMP positive opinion: new indication
Burosumab (Crysvita)
New indication (Hypophosphatemia, Familial, Hypophosphatemic Rickets, X-Linked Dominant, Osteomalacia). The wording is on the EMA page.
Orphan
CHMP opinion 23 Apr 2026 · Kyowa Kirin Holdings B.V.
EU · EU licence (European Commission)
Paltusotine (Palsonify)
Palsonify is indicated for the medical treatment of adult patients with acromegaly.
Orphan
CHMP opinion 26 Feb 2026 → EU licence 23 Apr 2026 · Crinetics Pharmaceuticals Europe GmbH
EU · EU licence (European Commission)
Remibrutinib (Rhapsido)
Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
CHMP opinion 26 Feb 2026 → EU licence 23 Apr 2026 · Novartis Europharm Limited
EU · CHMP positive opinion: new indication
Vamorolone (Agamree)
New indication (Muscular Dystrophy, Duchenne). The wording is on the EMA page.
Orphan
CHMP opinion 23 Apr 2026 · Santhera Pharmaceuticals (Deutschland) GmbH
EU · CHMP positive opinion: new indication
Venetoclax (Venclyxto)
New indication (Leukemia, Lymphocytic, Chronic, B-Cell). The wording is on the EMA page.
CHMP opinion 23 Apr 2026 · AbbVie Deutschland GmbH & Co. KG
EU · EU licence (European Commission)
Influenza mRNA vaccine;COVID-19 mRNA vaccine (mCombriax)
mCombriax is indicated for active immunisation for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. The use of this vaccine should be in accordance with official recommendations.
CHMP opinion 26 Feb 2026 → EU licence 20 Apr 2026 · Moderna Biotech Spain, S.L.
EU · EU licence (European Commission)
Tovorafenib (Ojemda)
Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)
OrphanConditional
CHMP opinion 26 Feb 2026 → EU licence 20 Apr 2026 · Ipsen Pharma
EU · EU licence (European Commission)
Clesrovimab (Enflonsia)
Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.
CHMP opinion 18 Sept 2025 → EU licence 15 Apr 2026 · Merck Sharp Dohme Limited
March 2026
EU · EU licence (European Commission)
Trivalent influenza vaccine (recombinant, prepared in cell culture) (Supemtek)
Supemtek is indicated for active immunisation for the prevention of influenza disease in adults and children from 9 years of age and older. Supemtek should be used in accordance with official recommendations.
CHMP opinion 29 Jan 2026 → EU licence 30 Mar 2026 · Sanofi Winthrop Industrie
EU · EU licence (European Commission)
Doxecitine;doxribtimine (Kygevvi)
Kygevvi is indicated for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
OrphanPRIMEExceptional circumstances
CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · UCB Pharma
EU · EU licence (European Commission)
Estetrol (Fylrevy)
Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in hysterectomised postmenopausal womenHormone replacement therapy (HRT) for oestrogen deficiency symptoms in non-hysterectomised postmenopausal women with at least 12 months since last menses.
CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · Gedeon Richter Plc.
EU · CHMP positive opinion: new indication
Lomitapide (Lojuxta)
New indication (Hypercholesterolemia). The wording is on the EMA page.
CHMP opinion 26 Mar 2026 · Chiesi Farmaceutici SpA
EU · EU licence (European Commission)
Lutetium (177Lu) chloride (Ilumira)
Ilumira is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.
CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · Shine Europe B.V.
EU · EU licence (European Commission)
Semaglutide (Kayshild)
Kayshild is indicated in conjunction with diet and exercise for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).
Conditional
CHMP opinion 29 Jan 2026 → EU licence 26 Mar 2026 · Novo Nordisk A/S
EU · EU licence (European Commission)
Belumosudil (Rezurock)
Rezurock is indicated for the treatment of adults and paediatric patients (12 years and older with a body weight of at least 40 kg) with chronic graft-versus-host disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.
OrphanConditional
CHMP opinion 29 Jan 2026 → EU licence 24 Mar 2026 · Sanofi Winthrop Industrie
February 2026
EU · CHMP negative opinion
Iloperidone (Iloperidone Vanda Pharmaceuticals)
Iloperidone is indicated for: treatment of schizophrenia in adults acute treatment of manic or mixed episodes associated with bipolar I disorder in adults
Negative
CHMP opinion 26 Feb 2026 · Vanda Pharmaceuticals Netherlands B.V.
EU · EU licence (European Commission)
Nogapendekin alfa inbakicept (Anktiva)
Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
Conditional
CHMP opinion 11 Dec 2025 → EU licence 16 Feb 2026 · Immunitybio Ireland Limited
EU · EU licence (European Commission)
COVID-19 mRNA vaccine (mNexspike)
mNEXSPIKE is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.
CHMP opinion 11 Dec 2025 → EU licence 12 Feb 2026 · Moderna Biotech Spain, S.L.
EU · EU licence (European Commission)
Aficamten (Myqorzo)
Myqorzo is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.
CHMP opinion 11 Dec 2025 → EU licence 12 Feb 2026 · Cytokinetics (Ireland) Limited
EU · EU licence (European Commission)
Depemokimab (Exdensur)
Asthma Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic… Show the full indication
Asthma Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP) Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
CHMP opinion 11 Dec 2025 → EU licence 12 Feb 2026 · GlaxoSmithKline Trading Services Limited
January 2026
EU · CHMP positive opinion: new indication
Finerenone (Kerendia)
New indication (Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2, Heart Failure). The wording is on the EMA page.
CHMP opinion 29 Jan 2026 · Bayer AG
EU · CHMP positive opinion: new indication
Hydrocortisone (Efmody)
New indication (Adrenal Hyperplasia, Congenital). The wording is on the EMA page.
CHMP opinion 29 Jan 2026 · Immedica Pharma AB
EU · CHMP positive opinion: new indication
Retifanlimab (Zynyz)
New indication (Carcinoma, Merkel Cell). The wording is on the EMA page.
Orphan
CHMP opinion 29 Jan 2026 · Incyte Biosciences Distribution B.V.
EU · EU licence (European Commission)
L-acetylleucine (Aqneursa)
Aqneursa is indicated for the treatment of neurological manifestations of Niemann-Pick type C (NPC) disease, in combination with miglustat, or as a monotherapy in patients where miglustat is not tolerated, in adults and children aged 6 years and older and weighing at least 20 kg.
Orphan
CHMP opinion 13 Nov 2025 → EU licence 19 Jan 2026 · Intrabio Ireland Limited
EU · EU licence (European Commission)
Donidalorsen (Dawnzera)
Dawnzera is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
CHMP opinion 13 Nov 2025 → EU licence 19 Jan 2026 · Otsuka Pharmaceutical Netherlands B.V.
EU · EU licence (European Commission)
Etuvetidigene autotemcel (Waskyra)
Waskyra is indicated for the treatment of patients aged 6 months and older with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom haematopoietic stem cell (HSC) transplantation is appropriate and no suitable human leukocyte antigen (HLA)-matched related haematopoietic stem cell donor is available.
OrphanAdvanced therapy
CHMP opinion 13 Nov 2025 → EU licence 9 Jan 2026 · Fondazione Telethon ETS
EU · EU licence (European Commission)
Imlunestrant (Inluriyo)
Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see… Show the full indication
Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see section 4.2).In pre- or perimenopausal women, or men, Inluriyo should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.
CHMP opinion 13 Nov 2025 → EU licence 9 Jan 2026 · Eli Lilly Nederland B.V.
EU · EU licence (European Commission)
Pertussis vaccine (recombinant, acellular, component, adsorbed) (VacPertagen)
VacPertagen is indicated for: - booster immunisation against pertussis of individuals 12 years of age and older,- passive protection against pertussis in early infancy following maternal immunisation during pregnancy.
CHMP opinion 13 Nov 2025 → EU licence 9 Jan 2026 · BioNet Europe
EU · EU licence (European Commission)
Deutetrabenazine (Austedo)
Treatment of moderate to severe tardive dyskinesia in adults.
CHMP opinion 5 Nov 2025 → EU licence 8 Jan 2026 · Teva GmbH
EU · EU licence (European Commission)
Germanium (68Ge) chloride;gallium (68Ga) chloride (GalenVita)
This radionuclide generator is not intended for direct use in patients. The sterile eluate (gallium (68Ga) chloride solution) from the radionuclide generator GalenVita is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such eluate, to be used… Show the full indication
This radionuclide generator is not intended for direct use in patients. The sterile eluate (gallium (68Ga) chloride solution) from the radionuclide generator GalenVita is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such eluate, to be used for positron emission tomography (PET) imaging.
CHMP opinion 13 Nov 2025 → EU licence 8 Jan 2026 · Curium Romania S.R.L.
EU · EU licence (European Commission)
Teplizumab (Teizeild)
Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.
PRIME
CHMP opinion 13 Nov 2025 → EU licence 8 Jan 2026 · Sanofi Winthrop Industrie
December 2025
EU · EU licence (European Commission)
Rilzabrutinib (Wayrilz)
Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)
Orphan
CHMP opinion 16 Oct 2025 → EU licence 22 Dec 2025 · Sanofi B.V.
EU · CHMP positive opinion: new indication
Inebilizumab (Uplizna)
New indication (Neuromyelitis Optica). The wording is on the EMA page.
CHMP opinion 11 Dec 2025 · Amgen Europe B.V.
EU · CHMP positive opinion: new indication
Voriconazole (Vfend)
New indication (Candidiasis, Mycoses, Aspergillosis). The wording is on the EMA page.
CHMP opinion 11 Dec 2025 · Pfizer Europe MA EEIG
November 2025
EU · EU licence (European Commission)
Nipocalimab (Imaavy)
Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
CHMP opinion 3 Nov 2025 → EU licence 28 Nov 2025 · Janssen Cilag International NV
EU · EU licence (European Commission)
Insulin icodec;semaglutide (Kyinsu)
Kyinsu is indicated for the treatment of adults with type 2 diabetes mellitus insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists as an adjunct to diet and exercise in addition to oral antidiabetic medicinal products. For study results with respect to combinations, effects on glycaemic control,… Show the full indication
Kyinsu is indicated for the treatment of adults with type 2 diabetes mellitus insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists as an adjunct to diet and exercise in addition to oral antidiabetic medicinal products. For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.
CHMP opinion 18 Sept 2025 → EU licence 24 Nov 2025 · Novo Nordisk A/S
EU · EU licence (European Commission)
Brensocatib (Brinsupri)
Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
PRIME
CHMP opinion 16 Oct 2025 → EU licence 18 Nov 2025 · Insmed Netherlands B.V.
EU · EU licence (European Commission)
Elinzanetant (Lynkuet)
Treatment of moderate to severe vasomotor symptoms (VMS).
CHMP opinion 18 Sept 2025 → EU licence 17 Nov 2025 · Bayer AG
EU · CHMP positive opinion: new indication
Eravacycline (Xerava)
New indication (Infection, Bacterial Infections). The wording is on the EMA page.
CHMP opinion 13 Nov 2025 · PAION Pharma GmbH
October 2025
EU · EU licence (European Commission)
Clascoterone (Winlevi)
Adults Winlevi is indicated for the treatment of acne vulgaris. Adolescents (from 12 to < 18 years of age) Winlevi is indicated for the treatment of facial acne vulgaris.
CHMP opinion 25 Aug 2025 → EU licence 17 Oct 2025 · Cassiopea S.p.A.
EU · CHMP positive opinion: new indication
Mitapivat (Pyrukynd)
New indication (Genetic Diseases, Inborn, Anemia, Hemolytic). The wording is on the EMA page.
Orphan
CHMP opinion 16 Oct 2025 · Agios Netherlands B.V.